Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE EBITDA Margin

EBITDA as a percentage of revenue.

Haemonetics CorporationNYSE: HAE

EBITDA Margin · Q1 FY2027 · quarter ended Jun 2026

EBITDA Margin narrows to 22.0%

EBITDA Margin was 22.0% in Q1 FY2027, down 7.1 pp from a year earlier. On a trailing-twelve-month basis it was 19.3%, down 8.7 pp year over year. Over 3 fiscal years it narrowed by 2.2 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2026 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 31.4% for the fiscal year ending Mar 2027, up from 20.1% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
22.0%+20.8 pp QoQ
Last fiscal yearMar 2026
20.1%-6.5 pp YoY
LTMJun 2026
19.3%-8.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.1 pp+7.8 pp+15.0 pp
1 year-6.5 pp+11.3 pp+17.8 pp
3 years-2.2 pp+11.8 pp+14.0 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
20.1%
Year-over-year change
-6.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's LTM Jun 2026 EBITDA Margin of 19.3% is the 4th highest of the 10 companies compared; the peer median is 17.0%.
  • Its year-over-year change of -8.7 pp is the 8th highest of 10, against a peer median of +1.3 pp.
  • Over three fiscal years its change of -2.2 pp compares with a peer median of +5.1 pp.
HAE Competitors Peer median
EBITDA Margin for HAE and competitors
Company Period LTM level YoY 3-year change
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202656.1% +0.7 pp+5.1 pp
LMATLeMaitre Vascular, Inc.LTM Mar 202637.6% +5.3 pp+13.5 pp
CONConcentra Group Holdings Parent, Inc.LTM Sep 202620.5% +1.3 pp-0.2 pp
HAEHaemonetics CorporationLTM Jun 202619.3% -8.7 pp-2.2 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
ITGRInteger Holdings CorporationLTM Jul 202617.0% +0.5 pp-0.6 pp
WRBYWarby Parker Inc.LTM Jun 20267.0% +2.0 pp+19.2 pp
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026-3.5% +10.1 pp+15.6 pp
QDELQuidelOrtho CorporationLTM Mar 2026-20.7% -31.1 pp-51.4 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-40.5% +584.3 pp+435.7 pp
Peer median (excluding HAE) 17.0%+1.3 pp+5.1 pp

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue993.2M1.17B1.31B1.36B1.33B
Cost of Revenue462.43M545.79M597.14M582.28M590.44M
Gross Profit530.77M622.87M711.92M778.55M743.59M
Gross Margin53.4%53.3%54.4%57.2%55.7%
Research & Development55.2M58.63M63.04M69.42M59.77M
Selling, General & Admin332.2M373.95M420.82M422.05M442.42M
Operating Expenses450.02M466.84M547.03M556.73M502.19M
Depreciation & Amortization97.75M93.31M97.22M115.59M111.72M
EBITDA202.92M260.51M304.05M362.69M268.45M
EBITDA Margin20.4%22.3%23.2%26.7%20.1%
Operating Income80.75M156.03M164.88M221.82M241.4M
Operating Margin8.1%13.4%12.6%16.3%18.1%
Interest Income00000
Interest Expense17.12M14.63M13.02M9.75M28.7M
Other Income / Expenses(17.12M)(14.63M)(13.02M)(9.75M)(113.37M)
Income Before Tax63.63M141.4M151.87M212.07M128.03M
Pre-Tax Margin6.4%12.1%11.6%15.6%9.6%
Income Tax Expense20.25M26M34.31M44.39M30.72M
Net Income43.38M115.4M117.56M167.68M97.31M
Net Margin4.4%9.9%9.0%12.3%7.3%
EPS (Basic)0.852.272.323.312.05
EPS (Diluted)0.842.242.293.312.05
Weighted Avg Shares51.05M50.78M50.71M50.33M47.18M
Weighted Avg Shares (Diluted)51.35M51.42M51.4M50.73M47.35M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.